Rahul Banerjee and Rafael Fonseca
Jun 26, 2025, 10:26
Rahul Banerjee: One of the Most Eloquent Arguments About 2nd-line CAR-T in Multiple Myeloma I’ve Ever Seen
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, posted on X by Rafael Fonseca, Hematologist at Mayo Clinic, adding:
“One of the most eloquent arguments about 2nd-line CAR-T in multiple myeloma I’ve ever seen – thanks for sharing your wisdom on this, Rafael!
In a different universe where CAR-T had come first, we would be reserving 2L D-Pd, Isa-Kd etc only for older frailer patients – wouldn’t even be debated.”
Quoting Rafael Fonseca‘s post:
“Using CARTs for first relapse in myeloma.”
More posts featuring Rahul Banerjee and Rafael Fonseca on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 14:50
Jun 26, 2025, 14:20
Jun 26, 2025, 13:31